Salomon Azoulay compensation by year
MBX Biosciences Summary Compensation Table · all 2 fiscal years held| Component | FY2024 | FY2025 |
|---|---|---|
| Salary | $234,400 | $488,500 |
| Bonus | $25,000 | $0 |
| Stock awards | $0 | $0 |
| Option awards | $2,742,770 | $740,034 |
| Non-equity incentive | $93,750 | $235,946 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $10,498 |
| Total | $3,095,920 | $1,474,978 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: MBX Biosciences, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-168536, and prior-year filings. Open the filing on EDGAR.
How this page was built: the MBX Biosciences, Inc. filed document, accession 0001193125-26-168536. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 30,946 | — | $16.00 |
| Option | 155,963 | — | $10.46 |
| Option | 90,000 | — | $10.49 |
Per the Outstanding Equity Awards at Fiscal Year-End table in MBX Biosciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
9 Form 4 lines since the FY2025 proxy (filed April 22, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-04 | Sale | — | 373 | $53.96 | 14,026 |
| 2026-08-04 | Sale | — | 370 | $65.77 | 14,399 |
| 2026-05-08 | Exercise or conversion derivative | 10b5-1 | 55,000 | $0.00 | 194,540 |
| 2026-05-08 | Exercise or conversion derivative | 10b5-1 | 15,003 | $0.00 | 30,008 |
| 2026-05-08 | Sale | 10b5-1 | 15,003 | $38.30 | 14,769 |
| 2026-05-08 | Exercise or conversion | 10b5-1 | 55,000 | $10.46 | 69,769 |
| 2026-05-08 | Sale | 10b5-1 | 55,000 | $38.38 | 14,769 |
| 2026-05-08 | Exercise or conversion | 10b5-1 | 15,003 | $16.00 | 29,772 |
The 8 most recent of 9 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
MBX Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| P. Kent Hawryluk | President and Chief Executive Officer | $2,990,867 |
| Richard Bartram | Former Chief Financial Officer | $1,496,275 |
| Salomon Azoulay · this page | Chief Medical Officer | $1,474,978 |
Salomon Azoulay's compensation dossier, MBX Biosciences
You have read Salomon Azoulay's totals and holdings. The dossier adds each equity grant MBX Biosciences disclosed for Salomon Azoulay and MBX Biosciences's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full MBX Biosciences compensation record
free company briefThis page is one person within MBX Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order MBX Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are MBX Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order MBX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.